{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:51:04Z","timestamp":1775915464219,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-023-02432-9","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T09:02:12Z","timestamp":1684918932000},"page":"1405-1416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chronic arthritides and bone structure: focus on rheumatoid arthritis\u2014an update"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7987-854X","authenticated-orcid":false,"given":"Osvaldo Daniel","family":"Messina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-5260","authenticated-orcid":false,"given":"Maritza","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A. Morales","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanza","family":"Arguissain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"2432_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00223-017-0373-1","volume":"102","author":"JH Shim","year":"2018","unstructured":"Shim JH, Stavre Z, Gravallese EM (2018) Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif Tissue Int 102:533\u2013546","journal-title":"Calcif Tissue Int"},{"key":"2432_CR2","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet 389:2328\u20132337","journal-title":"The Lancet"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s10067-017-3722-6","volume":"36","author":"G Boleto","year":"2017","unstructured":"Boleto G, Dram\u00e9 M, Lambrecht I et al (2017) Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. Clin Rheumatol 36:1699\u20131706","journal-title":"Clin Rheumatol"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00223-018-0401-9","volume":"102","author":"AM Dubrovsky","year":"2018","unstructured":"Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int 102:607\u2013618","journal-title":"Calcif Tissue Int"},{"key":"2432_CR5","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.3390\/ijms20235867","volume":"20","author":"G Adami","year":"2019","unstructured":"Adami G, Fassio A, Rossini M et al (2019) Osteoporosis in rheumatic diseases. Int J Mol Sci 20:5867","journal-title":"Int J Mol Sci"},{"key":"2432_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-019-0836-7","volume":"21","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis. Curr Rheumatol Rep 21:34","journal-title":"Curr Rheumatol Rep"},{"key":"2432_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11914-013-0183-y","volume":"12","author":"R Baum","year":"2014","unstructured":"Baum R, Gravallese EM (2014) Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep 12:9\u201316","journal-title":"Curr Osteoporos Rep"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0004563218759371","volume":"55","author":"JS Kenkre","year":"2018","unstructured":"Kenkre JS, Bassett JHD (2018) The bone remodelling cycle. Ann Clin Biochem 55:308\u2013327","journal-title":"Ann Clin Biochem"},{"key":"2432_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115628","volume":"141","author":"JM Delaisse","year":"2020","unstructured":"Delaisse JM, Andersen TL, Kristensen HB et al (2020) Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 141:115628","journal-title":"Bone"},{"key":"2432_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778078","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li J, Xie X et al (2021) Macrophage-osteoclast associations: origin, polarization, and subgroups. Front Immunol 12:778078","journal-title":"Front Immunol"},{"key":"2432_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jbmr.2599","volume":"31","author":"MM Weivoda","year":"2016","unstructured":"Weivoda MM, Ruan M, Hachfeld CM et al (2016) Wnt signaling inhibits osteoclast differentiation by activating canonical and noncanonical cAMP\/PKA pathways. J Bone Miner Res 31:65\u201375","journal-title":"J Bone Miner Res"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"2432_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.intimp.2018.04.019","volume":"59","author":"Y Ma","year":"2018","unstructured":"Ma Y, Zhang X, Wang M et al (2018) The serum level of Dickkopf-1 in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int Immunopharmacol 59:227\u2013232","journal-title":"Int Immunopharmacol"},{"key":"2432_CR14","first-page":"77","volume":"33","author":"M Rossini","year":"2015","unstructured":"Rossini M, Viapiana O, Adami S et al (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33:77\u201383","journal-title":"Clin Exp Rheumatol"},{"key":"2432_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/ard.2008.102046","volume":"69","author":"S Uderhardt","year":"2010","unstructured":"Uderhardt S, Diarra D, Katzenbeisser J et al (2010) Blockade of dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592\u2013597","journal-title":"Ann Rheum Dis"},{"key":"2432_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/art.40468","volume":"70","author":"X Li","year":"2018","unstructured":"Li X, Wang J, Zhan Z et al (2018) Inflammation intensity-dependent expression of osteoinductive Wnt proteins is critical for ectopic new bone formation in ankylosing spondylitis. Arthritis Rheumatol 70:1056\u20131070","journal-title":"Arthritis Rheumatol"},{"key":"2432_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00223-016-0161-3","volume":"99","author":"G Adami","year":"2016","unstructured":"Adami G, Orsolini G, Adami S et al (2016) Effects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritis. Calcif Tissue Int 99:360\u2013364","journal-title":"Calcif Tissue Int"},{"key":"2432_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Ishiguro N et al (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose\u2013response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to validate inhibitory effect on bone Erosion (DRIVE)\u2014a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983\u2013990","journal-title":"Ann Rheum Dis"},{"key":"2432_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Matsumoto T (2021) Sclerostin: from bench to bedside. JBMM 39:332\u2013340","journal-title":"JBMM"},{"key":"2432_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299\u20131309","journal-title":"Arthritis Rheum"},{"key":"2432_CR21","doi-asserted-by":"publisher","first-page":"rkac052","DOI":"10.1093\/rap\/rkac052","volume":"6","author":"AF Marsman","year":"2022","unstructured":"Marsman AF, Heslinga SC, Lems WF (2022) Does denosumab not only prevent fractures, but also bone erosions in rheumatoid arthritis? Rheumatol Adv Pract 6:rkac052","journal-title":"Rheumatol Adv Pract"},{"key":"2432_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000083","volume":"1","author":"M Favero","year":"2015","unstructured":"Favero M, Giusti A, Geusens P et al (2015) OsteoRheumatology: a new discipline? RMD Open 1:e000083","journal-title":"RMD Open"},{"key":"2432_CR23","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.3390\/ijms23158740","volume":"23","author":"P Pietschmann","year":"2022","unstructured":"Pietschmann P, Butylina M, Kerschan-Schindl K et al (2022) Mechanisms of systemic osteoporosis in rheumatoid arthritis. Int J Mol Sci 23:8740","journal-title":"Int J Mol Sci"},{"key":"2432_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. The Lancet 399:1080\u20131092","journal-title":"The Lancet"},{"key":"2432_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","volume":"71","author":"C Cheng","year":"2020","unstructured":"Cheng C, Wentworth K, Shoback DM (2020) New frontiers in osteoporosis therapy. Annu Rev Med 71:277\u2013288","journal-title":"Annu Rev Med"},{"key":"2432_CR26","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/jcm9113439","volume":"9","author":"S Fabre","year":"2020","unstructured":"Fabre S, Funck-Brentano T, Cohen-Solal M (2020) Anti-sclerostin antibodies in osteoporosis and other bone diseases. J Clin Med 9:3439","journal-title":"J Clin Med"},{"key":"2432_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"2432_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002055","volume":"8","author":"G Adami","year":"2022","unstructured":"Adami G, Pontalti M, Cattani G et al (2022) Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. RMD Open 8:e002055","journal-title":"RMD Open"},{"key":"2432_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D et al (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15","journal-title":"Bone Res"},{"key":"2432_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.601618","volume":"7","author":"I Llorente","year":"2020","unstructured":"Llorente I, Garc\u00eda-Casta\u00f1eda N, Valero C et al (2020) Osteoporosis in rheumatoid arthritis: dangerous liaisons. Front Med 7:601618","journal-title":"Front Med"},{"key":"2432_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1833-y","volume":"21","author":"I Hafstr\u00f6m","year":"2019","unstructured":"Hafstr\u00f6m I, Ajeganova S, Forslind K et al (2019) Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort. Arthritis Res Ther 21:1\u20139","journal-title":"Arthritis Res Ther"},{"key":"2432_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","volume":"28","author":"CAF Zerbini","year":"2017","unstructured":"Zerbini CAF, Clark P, Mendez-Sanchez L et al (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429\u2013446","journal-title":"Osteoporos Int"},{"key":"2432_CR33","doi-asserted-by":"publisher","first-page":"10922","DOI":"10.3390\/ijms222010922","volume":"22","author":"N Kondo","year":"2021","unstructured":"Kondo N, Kuroda T, Kobayashi D (2021) Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci 22:10922","journal-title":"Int J Mol Sci"},{"key":"2432_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","volume":"65","author":"AK Rana","year":"2018","unstructured":"Rana AK, Li Y, Dang Q et al (2018) Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 65:348\u2013359","journal-title":"Int Immunopharmacol"},{"key":"2432_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ncprheum0036","volume":"1","author":"G Schett","year":"2005","unstructured":"Schett G, Hayer S, Zwerina J et al (2005) Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Rev Rheumatol 1:47\u201354","journal-title":"Nat Rev Rheumatol"},{"key":"2432_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen Z, Bozec A, Ramming A et al (2019) Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol 15:9\u201317","journal-title":"Nat Rev Rheumatol"},{"key":"2432_CR37","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/ijms22020686","volume":"22","author":"CY Wu","year":"2021","unstructured":"Wu CY, Yang HY, Luo SF et al (2021) From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci 22:686","journal-title":"Int J Mol Sci"},{"key":"2432_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3389\/fimmu.2019.01483","volume":"10","author":"U Steffen","year":"2019","unstructured":"Steffen U, Schett G, Bozec A (2019) How autoantibodies regulate osteoclast induced bone loss in rheumatoid arthritis. Front Immunol 10:1483","journal-title":"Front Immunol"},{"key":"2432_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102392","volume":"110","author":"MA van Delft","year":"2020","unstructured":"van Delft MA, Huizinga TW (2020) An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 110:102392","journal-title":"J Autoimmun"},{"key":"2432_CR40","doi-asserted-by":"crossref","first-page":"1759720X2110225","DOI":"10.1177\/1759720X211022533","volume":"13","author":"P Studenic","year":"2021","unstructured":"Studenic P, Alunno A, Sieghart D et al (2021) Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Thera Adv Musculoskelet Dis 13:1759720X211022533","journal-title":"Thera Adv Musculoskelet Dis"},{"key":"2432_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch J (2008) Fc\u03b3 receptors as regulators of immune responses. Nat Rev Immunol 8:34\u201347","journal-title":"Nat Rev Immunol"},{"key":"2432_CR42","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Investig 122:1791\u20131802","journal-title":"J Clin Investig"},{"key":"2432_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/BOR.0000000000000789","volume":"33","author":"KD Wysham","year":"2021","unstructured":"Wysham KD, Baker JF, Shoback DM (2021) Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol 33:270\u2013276","journal-title":"Curr Opin Rheumatol"},{"key":"2432_CR44","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1080\/14656566.2020.1787381","volume":"21","author":"HG Raterman","year":"2020","unstructured":"Raterman HG, Bultink IE, Lems WF (2020) Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin Pharmacother 21:1725\u20131737","journal-title":"Expert Opin Pharmacother"},{"key":"2432_CR45","doi-asserted-by":"publisher","first-page":"101773","DOI":"10.1016\/j.berh.2022.101773","volume":"36","author":"R Baker","year":"2022","unstructured":"Baker R, Narla R, Baker JF et al (2022) Risk factors for osteoporosis and fractures in rheumatoid arthritis. Best Pract Res Clin Rheumatol 36:101773","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2432_CR46","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/jcm9103361","volume":"9","author":"P Fardellone","year":"2020","unstructured":"Fardellone P, Salawati E, Le Monnier L et al (2020) Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review. J Clin Med 9:3361","journal-title":"J Clin Med"},{"key":"2432_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","volume":"21","author":"K Michaud","year":"2007","unstructured":"Michaud K, Wolfe F (2007) Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:885\u2013906","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2432_CR48","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3899\/jrheum.101196","volume":"38","author":"NC Wright","year":"2011","unstructured":"Wright NC, Walitt BT, Eaton CB et al (2011) Arthritis increases the risk for fractures-results from the women\u2019s health initiative. J Rheumatol 38:1680\u20131688","journal-title":"J Rheumatol"},{"key":"2432_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/annrheumdis-2021-221093","volume":"81","author":"I Yoshii","year":"2022","unstructured":"Yoshii I, Sawada N, Chijiwa T et al (2022) Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis. Ann Rheum Dis 81:296\u2013299","journal-title":"Ann Rheum Dis"},{"key":"2432_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3056","volume":"12","author":"D Aeberli","year":"2010","unstructured":"Aeberli D, Eser P, Bonel H et al (2010) Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study. Arthritis Res Ther 12:1\u201310","journal-title":"Arthritis Res Ther"},{"key":"2432_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02503-0","volume":"23","author":"S Jin","year":"2021","unstructured":"Jin S, Li M, Wang Q et al (2021) Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. Arthritis Res Ther 23:1\u201312","journal-title":"Arthritis Res Ther"},{"key":"2432_CR52","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/jbmr.3025","volume":"32","author":"D Simon","year":"2017","unstructured":"Simon D, Kleyer A, Stemmler F et al (2017) Age- and sex-dependent changes of intra-articular cortical and trabecular bone structure and the effects of rheumatoid arthritis. J Bone Miner Res 32:722\u2013730","journal-title":"J Bone Miner Res"},{"key":"2432_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/14782715221088979","volume":"52","author":"P Pruthi","year":"2022","unstructured":"Pruthi P, Singh AP (2022) Bilateral radial stress fractures in rheumatoid arthritis. J R Coll Physicians Edinb 52:57\u201358","journal-title":"J R Coll Physicians Edinb"},{"key":"2432_CR54","doi-asserted-by":"publisher","first-page":"e0255542","DOI":"10.1371\/journal.pone.0255542","volume":"16","author":"PH Lin","year":"2021","unstructured":"Lin PH, Yu SF, Chen JF et al (2021) Risk factor analysis of fragility fractures in rheumatoid arthritis: a 3-year longitudinal, real-world, observational, cohort study. PLoS ONE 16:e0255542","journal-title":"PLoS ONE"},{"key":"2432_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40520-021-01823-0","volume":"33","author":"OD Messina","year":"2021","unstructured":"Messina OD, Vidal LF, Vidal M et al (2021) Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res 33:793\u2013804","journal-title":"Aging Clin Exp Res"},{"key":"2432_CR56","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TV Staa","year":"2006","unstructured":"Staa TV, Geusens P, Bijlsma JWJ et al (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104\u20133112","journal-title":"Arthritis Rheum"},{"key":"2432_CR57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","volume":"31","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388\u2013393","journal-title":"Curr Opin Rheumatol"},{"key":"2432_CR58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816","journal-title":"Osteoporos Int"},{"key":"2432_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","volume":"11","author":"R Rizzoli","year":"2015","unstructured":"Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98\u2013109","journal-title":"Nat Rev Rheumatol"},{"key":"2432_CR60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J et al (2022) Secondary osteoporosis. Endocr Rev 43:240\u2013313","journal-title":"Endocr Rev"},{"key":"2432_CR61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","volume":"81","author":"E Wiebe","year":"2022","unstructured":"Wiebe E, Huscher D, Schaumburg D et al (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis 81:1313\u20131322","journal-title":"Ann Rheum Dis"},{"key":"2432_CR62","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/annrheumdis-2020-218758","volume":"80","author":"S Abtahi","year":"2021","unstructured":"Abtahi S, Driessen JH, Burden AM et al (2021) Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 80:423\u2013431","journal-title":"Ann Rheum Dis"},{"key":"2432_CR63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/BOR.0000000000000291","volume":"28","author":"BN Andersen","year":"2016","unstructured":"Andersen BN, Johansen PB, Abrahamsen B (2016) Proton pump inhibitors and osteoporosis. Curr Op Rheumatol 28:420\u2013425","journal-title":"Curr Op Rheumatol"},{"key":"2432_CR64","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fendo.2020.00473","volume":"11","author":"YT Ghebre","year":"2020","unstructured":"Ghebre YT (2020) Proton pump inhibitors and osteoporosis: is collagen a direct target? Front Endocrinol 11:473","journal-title":"Front Endocrinol"},{"key":"2432_CR65","doi-asserted-by":"crossref","unstructured":"Briganti SI, Naciu AM, Tabacco G et al (2021) Proton pump inhibitors and fractures in adults: a critical appraisal and review of the literature. Int J Endocrinol 2021:8902367","DOI":"10.1155\/2021\/8902367"},{"key":"2432_CR66","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/jgs.13661","volume":"63","author":"AM Hinson","year":"2015","unstructured":"Hinson AM, Wilkerson BM, Rothman-Fitts I (2015) Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc 63:2070\u20132073","journal-title":"J Am Geriatr Soc"},{"key":"2432_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X221142346","volume":"14","author":"KE Hansen","year":"2022","unstructured":"Hansen KE, Mortezavi M, Nagy E et al (2022) Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis 14:1\u201313","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2432_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116137","volume":"153","author":"B Batteux","year":"2021","unstructured":"Batteux B, Bennis Y, Bodeau S et al (2021) Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase\u00ae). Bone 153:116137","journal-title":"Bone"},{"key":"2432_CR69","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/acr2.11292","volume":"3","author":"A Pawar","year":"2021","unstructured":"Pawar A, Desai RJ, He M et al (2021) Comparative risk of nonvertebral fractures among patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. ACR Open Rheumatol 3:531\u2013539","journal-title":"ACR Open Rheumatol"},{"key":"2432_CR70","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/ard.60.5.521","volume":"60","author":"TM Huusko","year":"2001","unstructured":"Huusko TM, Korpela M, Karppi P et al (2001) Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 60:521\u2013522","journal-title":"Ann Rheum Dis"},{"key":"2432_CR71","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00296-012-2375-7","volume":"33","author":"MH Abdel Meguid","year":"2013","unstructured":"Abdel Meguid MH, Hamad YH, Swilam RS et al (2013) Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 33:697\u2013703","journal-title":"Rheumatol Int"},{"key":"2432_CR72","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/acr.23133","volume":"69","author":"J Yue","year":"2017","unstructured":"Yue J, Griffith JF, Xiao F et al (2017) Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care Res 69:1156\u20131163","journal-title":"Arthritis Care Res"},{"key":"2432_CR73","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jbspin.2016.05.010","volume":"84","author":"T Hasegawa","year":"2016","unstructured":"Hasegawa T, Kaneko Y, Izumi K et al (2016) Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. J Bone Spine 84:379\u2013380","journal-title":"J Bone Spine"},{"key":"2432_CR74","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fendo.2019.00817","volume":"10","author":"MA Clynes","year":"2019","unstructured":"Clynes MA, Jameson K, Prieto-Alhambra D et al (2019) Impact of rheumatoid arthritis and its management on falls, fracture and bone mineral density in UK Biobank. Front Endocrinol 10:817","journal-title":"Front Endocrinol"},{"key":"2432_CR75","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00198-019-04966-z","volume":"30","author":"WJ Hong","year":"2019","unstructured":"Hong WJ, Chen W, Yeo KJ et al (2019) Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan. Osteoporos Int 30:1617\u20131625","journal-title":"Osteoporos Int"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-023-02432-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:15:40Z","timestamp":1687328140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-023-02432-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1007\/s40520-023-02432-9","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"8 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}